Dexamethasone May Be Detrimental to Immunotherapy in Glioblastoma Patients

Historically, patients with glioblastoma have been empirically treated with dexamethasone, even without symptoms, with many clinicians prescribing steroids for prolonged periods of time, out of a concern that patients may start to develop edema. Preclinical and clinical data indicate that concurrent dexamethasone therapy may be detrimental to immunotherapeutic approaches for patients with glioblastoma (GBM).

The post Dexamethasone May Be Detrimental to Immunotherapy in Glioblastoma Patients appeared first on GEN – Genetic Engineering and Biotechnology News.

Published on Wed, 25 Nov 2020 21:00:58 +0000 with keywords salesforce short link